Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Gail D, Lewis"'
Autor:
Gail D. Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T. Fields, Genee Lee, Donglu Zhang, Peter S. Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M. Violet Lee, Ola Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Hamilton, Patricia LoRusso, Ian Krop, Melissa M. Schutten, Renee Commerford, Mark X. Sliwkowski, Eunpi Cho
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzuma
Externí odkaz:
https://doaj.org/article/654b41b090ea4a87be21fb42ec554dae
Autor:
Sanne L. de Haas, Dennis J. Slamon, Miguel Martin, Michael F. Press, Gail D. Lewis, Chiara Lambertini, Aleix Prat, Vanesa Lopez-Valverde, Thomas Boulet, Sara A. Hurvitz
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-14 (2023)
Abstract Background KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II–III breast cancer. We inve
Externí odkaz:
https://doaj.org/article/dc9caefbaf5f4cbcb3bf0e94081b2deb
Autor:
Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik
Publikováno v:
Clinical Cancer Research. 29:1569-1581
Purpose: In KATHERINE, adjuvant T-DM1 reduced risk of disease recurrence or death by 50% compared with trastuzumab in patients with residual invasive breast cancer after neoadjuvant therapy (NAT) comprised of HER2-targeted therapy and chemotherapy. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f0085564ba3aaa9a88c1ad734a24b84
https://doi.org/10.1158/1078-0432.ccr-22-1989
https://doi.org/10.1158/1078-0432.ccr-22-1989
Autor:
Thuss-Patience, Peter C, Shah, Manish A, Ohtsu, Atsushi, Van Cutsem, Eric, Ajani, Jaffer A, Castro, Hugo, Mansoor, Wasat, Chung, Hyun Cheol, Bodoky, Gyorgy, Shitara, Kohei, Phillips, Gail D Lewis, van der Horst, Tina, Harle-Yge, Marie-Laurence, Althaus, Betsy L, Kang, Yoon-Koo
Publikováno v:
In The Lancet Oncology May 2017 18(5):640-653
Autor:
Akshay T. Krishnamurty, Justin A. Shyer, Minh Thai, Vineela Gandham, Matthew B. Buechler, Yeqing Angela Yang, Rachana N. Pradhan, Amber W. Wang, Patricia L. Sanchez, Yan Qu, Beatrice Breart, Cécile Chalouni, Debra Dunlap, James Ziai, Justin Elstrott, Neelie Zacharias, Weiguang Mao, Rebecca K. Rowntree, Jack Sadowsky, Gail D. Lewis, Thomas H. Pillow, Barzin Y. Nabet, Romain Banchereau, Lucinda Tam, Roger Caothien, Natasha Bacarro, Merone Roose-Girma, Zora Modrusan, Sanjeev Mariathasan, Sören Müller, Shannon J. Turley
Publikováno v:
Nature. 611:148-154
Recent single-cell studies of cancer in both mice and humans have identified the emergence of a myofibroblast population specifically marked by the highly restricted leucine-rich-repeat-containing protein 15 (LRRC15)1–3. However, the molecular sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1180240064ddca96a7dbfb51299c508a
https://doi.org/10.1038/s41586-022-05272-1
https://doi.org/10.1038/s41586-022-05272-1
Autor:
Mark Basik, Sanne de Haas, Malgorzata Nowicka, Gail D. Lewis, Chunyan Song, Thomas Boulet, Peter C. Lucas, Charles E. Geyer, Eleftherios P. Mamounas, Sibylle Loibl, Chiun-Sheng Huang, Norman Wolmark, Michael Untch, Max S. Mano, Katherine L. Pogue-Geile, Peter A. Fasching, Chiara Lambertini, Carsten Denkert
HER2, PD-L1, and Five-Gene Signature Quartile Analysis. IDFS by HER2 gene expression quartile (A) in the trastuzumab arm; and (B) in the T-DM1 arm; (C) treatment effect on IDFS by HER2 gene expression quartile; (D) effect of HER2 gene expression quar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15dcae2c2ac83746ece008bb6e2aaeab
https://doi.org/10.1158/1078-0432.22633072
https://doi.org/10.1158/1078-0432.22633072
Autor:
Lori S. Friedman, Anwesha Dey, Donald S. Kirkpatrick, Steven T. Staben, Shiva Malek, Alan G. Olivero, Timothy P. Heffron, Laurent Salphati, Gail D. Lewis Phillips, Emile G. Plise, Jonathan Cheong, Jeffrey J. Wallin, Jane Guan, Nicholas Endres, Stephen Schmidt, Eric Stawiski, William F. Forrest, Lilian Phu, Rebecca Hong, Michelle A. Nannini, Deepak Sampath, Mark Merchant, Jason Oeh, Marc Hafner, Emily J. Hanan, Kyle A. Edgar, Kyung W. Song
RTK activity plays a key role in regulating p110a degradation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3f61f91c6eba4539d57e9ffe438944
https://doi.org/10.1158/2159-8290.22540279
https://doi.org/10.1158/2159-8290.22540279
Autor:
Gail D. Lewis Phillips, Jennifer A. Lacap, Lisa M. Crocker, Mark X. Sliwkowski, Daniela Bumbaca Yadav, Ben-Quan Shen, Jun Guo, Guangmin Li
Supplemental Figure 1. Upregulated BHLHE41 in KPL-4 TR and BT-474M1 TR cells does not confer resistance to T-DM1. Supplemental Figure 2. Flow cytometry analysis of HER2 and MDR1 expression in KPL-4 P and TR cells, and tumor derived KPL-4 TR cells. Su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b709490029dc3505c4b128d699e8aa2c
https://doi.org/10.1158/1535-7163.22507053
https://doi.org/10.1158/1535-7163.22507053
Autor:
Gail D. Lewis Phillips, Jennifer A. Lacap, Lisa M. Crocker, Mark X. Sliwkowski, Daniela Bumbaca Yadav, Ben-Quan Shen, Jun Guo, Guangmin Li
Differentially expressed genes in T-DM1-resistant BT-474M1 cells with respect to the parental cell line (fold change > 2 fold and P < 0.05 of individual probes for a given gene in the microarray)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e247bc5c253cda1cb96b06e6f3477c1
https://doi.org/10.1158/1535-7163.22507044.v1
https://doi.org/10.1158/1535-7163.22507044.v1
Autor:
Lori S. Friedman, Anwesha Dey, Donald S. Kirkpatrick, Steven T. Staben, Shiva Malek, Alan G. Olivero, Timothy P. Heffron, Laurent Salphati, Gail D. Lewis Phillips, Emile G. Plise, Jonathan Cheong, Jeffrey J. Wallin, Jane Guan, Nicholas Endres, Stephen Schmidt, Eric Stawiski, William F. Forrest, Lilian Phu, Rebecca Hong, Michelle A. Nannini, Deepak Sampath, Mark Merchant, Jason Oeh, Marc Hafner, Emily J. Hanan, Kyle A. Edgar, Kyung W. Song
PIK3CA is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have entered clinical trials, with early-phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fd67c192262a4b6f3e1d058d9266830
https://doi.org/10.1158/2159-8290.c.6549343
https://doi.org/10.1158/2159-8290.c.6549343